The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Poison control experts say calls related to GLP-1 weight-loss drugs like Wegovy and Zepbound are rising, with symptoms like ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

Side effects tended to be mild to moderate and included gastrointestinal issues such as nausea, constipation, diarrhea, and vomiting. About 6 percent of people on Zepbound and 8 percent of people ...

Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...